AMLX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates

Nov 5, 2026

8-K

Amylyx Pharmaceuticals Enters Supply Agreements for Avexitide

Sep 8, 2026

8-K

Amylyx Pharmaceuticals Announces Pricing of $500 Million Common Stock Offering

Aug 20, 2026

8-K

Amylyx Announces Positive Topline Results from Phase 3 LUCIDITY Trial of Avexitide for Post-Bariatric Hypoglycemia (PBH)

Aug 18, 2026

8-K

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

Aug 18, 2026

8-K

Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Pipeline Updates

Aug 6, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Aug 20, 2026

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $350,000,000 | Bank: Leerink Partners, Morgan Stanley, Guggenheim Securities, LifeSci Capital

Aug 18, 2026

424B5

REGISTERED OFFERING

Sep 10, 2025

424B5

PENDING FIXED PRICE OFFERING | Bank: H.C. Wainwright & Co.

Sep 9, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Jan 10, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Jan 10, 2025

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 3, 2026

S-3ASR

March 2026 SHELF

Mar 3, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 4, 2025

S-3

Form S-3 - Registration statement under Securities Act of 1933

Mar 4, 2025

POSASR

Form POSASR - Post-effective Amendment to an automatic shelf registration statement

Mar 4, 2025

S-8

Registration

Feb 22, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 23, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 23, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 24, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 24, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 24, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 24, 2024

Ownerships

TYPE

HEADLINE

FILED AT

144

NEWForm 144 - Report of proposed sale of securities

Nov 9, 2026

144

NEWForm 144 - Report of proposed sale of securities

Nov 9, 2026

144

NEWForm 144 - Report of proposed sale of securities

Nov 9, 2026

MILNE GEORGE M JR (Reporting)

Oct 7, 2026

144

Form 144 - Report of proposed sale of securities

Oct 5, 2026

Bedrosian Camille L (Reporting)

Sep 14, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 27, 2025

CORRESP

Form CORRESP - Correspondence

Mar 24, 2025

LETTER

Form UPLOAD - SEC-generated letter

Mar 5, 2025

LETTER

Form UPLOAD - SEC-generated letter

Dec 20, 2023

CORRESP

Form CORRESP - Correspondence

Dec 19, 2023

LETTER

Form UPLOAD - SEC-generated letter

Dec 5, 2023

Amylyx Pharmaceuticals, Inc. AMLX · SEC Filings